Your browser doesn't support javascript.
loading
A novel combination treatment with apremilast and tumor necrosis factor inhibitor for a patient with refractory intestinal Behcet's disease.
Fukui, S; Kawaai, S; Tamaki, H; Fukuda, K; Okada, M.
Affiliation
  • Fukui S; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Kawaai S; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Tamaki H; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Fukuda K; Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan.
  • Okada M; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
Scand J Rheumatol ; 51(1): 81-82, 2022 01.
Article in En | MEDLINE | ID: mdl-34232114
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Behcet Syndrome / Intestinal Diseases Limits: Humans Language: En Journal: Scand J Rheumatol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Behcet Syndrome / Intestinal Diseases Limits: Humans Language: En Journal: Scand J Rheumatol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United kingdom